Evidence map›Paper›PMID 32912304›Full record

ArticleRespiratory research2020

Azithromycin ameliorates sulfur dioxide-induced airway epithelial damage and inflammatory responses.

Jon Petur Joelsson, Jennifer A Kricker, Ari J Arason, Snaevar Sigurdsson, Bryndis Valdimarsdottir, Fridrik Runar Gardarsson, Clive P Page, Fredrik Lehmann, Thorarinn Gudjonsson, Saevar Ingthorsson

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Repetitive sulfur dioxide exposure in mice models post-deployment respiratory syndrome.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Role of air pollutants in airway epithelial barrier dysfunction in asthma and COPD.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Jon Petur JoelssonStem Cell Research Unit, BioMedical Center, School of Health Sciences, University of Iceland, Reykjavík, Iceland.
Jennifer A KrickerStem Cell Research Unit, BioMedical Center, School of Health Sciences, University of Iceland, Reykjavík, Iceland.
Ari J ArasonStem Cell Research Unit, BioMedical Center, School of Health Sciences, University of Iceland, Reykjavík, Iceland.
Snaevar SigurdssonBiomedical Center, University of Iceland, Reykjavík, Iceland.
Bryndis ValdimarsdottirStem Cell Research Unit, BioMedical Center, School of Health Sciences, University of Iceland, Reykjavík, Iceland.
Fridrik Runar GardarssonEpiEndo Pharmaceuticals, Reykjavík, Iceland.
Clive P PageEpiEndo Pharmaceuticals, Reykjavík, Iceland.
Fredrik LehmannEpiEndo Pharmaceuticals, Reykjavík, Iceland.
Thorarinn GudjonssonStem Cell Research Unit, BioMedical Center, School of Health Sciences, University of Iceland, Reykjavík, Iceland.
Saevar IngthorssonStem Cell Research Unit, BioMedical Center, School of Health Sciences, University of Iceland, Reykjavík, Iceland. saevari@hi.is.ORCID http://orcid.org/0000-0001-8480-9680
University of Iceland · ISEndo Pharmaceuticals (United States) · USReykjavík University · ISKing's College London · GB

Funding

Icelandic Centre for Research 186943-0611
6 · The paper itself

Abstract

backgroundThe airway epithelium (AE) forms the first line of defence against harmful particles and pathogens. Barrier failure of the airway epithelium contributes to exacerbations of a range of lung diseases that are commonly treated with Azithromycin (AZM). In addition to its anti-bacterial function, AZM has immunomodulatory effects which are proposed to contribute to its clinical effectiveness. In vitro studies have shown the AE barrier-enhancing effects of AZM. The aim of this study was to analyze whether AE damage caused by inhalation of sulfur dioxide (SO

methodsThe leakiness of the AE barrier was evaluated after SO

resultsAZM pre-treatment (2 mg/kg p.o. 5 times/week for 2 weeks) resulted in reduced glutathione-S-transferases in BALF of SO

conclusionsUsing a mouse model of AE barrier dysfunction we provide evidence for the protective effects of AZM in vivo, possibly through stabilizing the intracellular microenvironment and reducing inflammatory responses. Our data provide insight into the mechanisms contributing to the efficacy of AZM in the treatment of airway diseases.

Indexed as

Air PollutantsAnimalsAnti-Bacterial AgentsAzithromycinBronchoalveolar Lavage FluidFemaleInhalation ExposureLungMiceMice, Inbred C57BLRespiratory MucosaSulfur DioxideAir PollutantsAnti-Bacterial AgentsAzithromycinSulfur DioxideAzithromycinGlutathione-S-transferaseImmunomodulationLamellar bodiesLung barrier enhancement

Identifiers

PMID32912304
PMCPMC7488110
OpenAlexW3084223373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.